Aileron Therapeutics, Inc. (ALRN)
NASDAQ: ALRN · Real-Time Price · USD
2.790
-0.060 (-2.17%)
Dec 3, 2024, 12:13 PM EST - Market open
Aileron Therapeutics Employees
Aileron Therapeutics had 15 employees as of December 31, 2023. The number of employees increased by 9 or 150.00% compared to the previous year.
Employees
15
Change (1Y)
9
Growth (1Y)
150.00%
Revenue / Employee
n/a
Profits / Employee
-$1,949,400
Market Cap
60.45M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Burning Rock Biotech | 786 |
Apyx Medical | 252 |
Champions Oncology | 210 |
VolitionRx | 110 |
Boundless Bio | 72 |
Spero Therapeutics | 46 |
Forian | 37 |
Cellectar Biosciences | 20 |
ALRN News
- 18 days ago - Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - PRNewsWire
- 20 days ago - Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - PRNewsWire
- 4 weeks ago - Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma - PRNewsWire
- 7 weeks ago - Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis - PRNewsWire
- 2 months ago - Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - PRNewsWire
- 3 months ago - Aileron Therapeutics to Present at the 8th Annual IPF Summit - PRNewsWire
- 3 months ago - Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights - PRNewsWire
- 4 months ago - Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - PRNewsWire